QURE · Insider Trading
uniQure N.V.
Every open-market purchase and sale reported by QURE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-07 | Matthew C Kapusta | CEO, Managing Director | MIXED | — | −$543.27K |
| 2026-07-02 | Jack Kaye | Director | MIXED | — | −$486.80K |
| 2026-07-02 | Walid Abi-Saab | Chief Medical Officer | MIXED | −20,000 | −$1.34M |
| 2026-06-26 | Matthew C Kapusta | CEO, Managing Director | MIXED | −2,568 | −$729.69K |
| 2026-06-22 | Madhavan Balachandran | Director | MIXED | — | −$234.68K |
| 2026-06-22 | Matthew C Kapusta | CEO, Managing Director | MIXED | −138,863 | −$8.01M |
| 2026-06-22 | Jack Kaye | Director | MIXED | — | −$57.50K |
| 2026-06-17 | Jeannette Potts | Chief Legal Officer | Sell | −5,237 | −$144.91K |
| 2026-06-17 | Madhavan Balachandran | Director | MIXED | — | −$193.60K |
| 2026-06-12 | Kylie O'Keefe | Chief Customer & Strat Officer | Sell | −15,936 | −$431.23K |
| 2026-06-12 | Rachelle Suzanne Jacques | Director | MIXED | +5,557 | −$53.93K |
| 2026-06-12 | Jack Kaye | Director | MIXED | +5,557 | −$53.93K |
| 2026-06-12 | Leonard E Post | Director | MIXED | +5,557 | −$53.93K |
| 2026-06-12 | David D. Meek | Director | MIXED | +5,557 | −$53.93K |
| 2026-06-12 | Robert Gut | Director | MIXED | −83 | −$228.06K |
| 2026-06-12 | Jeremy P. Springhorn | Director | MIXED | +5,557 | −$53.93K |
| 2026-06-12 | Madhavan Balachandran | Director | MIXED | +5,557 | −$53.93K |
| 2026-06-05 | Jack Kaye | Director | MIXED | — | −$36.95K |
| 2026-05-12 | Walid Abi-Saab | Chief Medical Officer | MIXED | −20,000 | −$987.75K |
| 2026-03-09 | Kylie O'Keefe | Chief Customer & Strat Officer | A | +19,800 | — |
| 2026-03-06 | Matthew C Kapusta | CEO, Managing Director | MIXED | +56,019 | −$132.10K |
| 2026-03-06 | Christian Klemt | Chief Financial Officer | MIXED | +27,600 | −$108.72K |
| 2026-03-06 | Jeannette Potts | Chief Legal Officer | MIXED | +31,988 | −$30.91K |
| 2026-03-06 | Walid Abi-Saab | Chief Medical Officer | MIXED | +40,892 | −$7.32K |
| 2026-03-04 | Walid Abi-Saab | Chief Medical Officer | Sell | −1,660 | −$16.52K |
| 2026-03-04 | Christian Klemt | Chief Financial Officer | Sell | −12,532 | −$124.69K |
| 2026-03-04 | Matthew C Kapusta | CEO, Managing Director | Sell | −34,437 | −$342.65K |
| 2026-03-04 | Jeannette Potts | Chief Legal Officer | Sell | −8,578 | −$85.35K |
| 2026-02-27 | Christian Klemt | Chief Financial Officer | Sell | −6,217 | −$148.34K |
| 2026-02-27 | Matthew C Kapusta | CEO, Managing Director | Sell | −12,378 | −$295.34K |
| 2026-01-14 | Robert Gut | Director | MIXED | −7,803 | −$379.72K |
| 2026-01-12 | Jack Kaye | Director | MIXED | — | −$50.42K |
| 2025-11-10 | Robert Gut | Director | MIXED | −15,594 | −$784.49K |
| 2025-11-06 | Jack Kaye | Director | MIXED | — | −$793.98K |
| 2025-09-26 | Christian Klemt | Chief Financial Officer | MIXED | — | −$825.48K |
| 2025-09-26 | Matthew C Kapusta | CEO, Managing Director | MIXED | — | −$7.91M |
| 2025-07-01 | Walid Abi-Saab | Chief Medical Officer | Sell | −1,466 | −$20.41K |
| 2025-06-24 | Leonard E Post | Director | Sell | −2,112 | −$30.52K |
| 2025-06-24 | Madhavan Balachandran | Director | Sell | −2,112 | −$30.52K |
| 2025-06-24 | David D. Meek | Director | Sell | −2,112 | −$30.52K |
| 2025-06-24 | Jack Kaye | Director | Sell | −2,112 | −$30.52K |
| 2025-06-24 | Rachelle Suzanne Jacques | Director | Sell | −2,112 | −$30.52K |
| 2025-06-24 | Robert Gut | Director | Sell | −3,336 | −$48.21K |
| 2025-06-24 | Jeremy P. Springhorn | Director | Sell | −2,112 | −$30.52K |
| 2025-06-20 | Jeannette Potts | Chief Legal Officer | Sell | −4,670 | −$70.70K |
| 2025-06-13 | Madhavan Balachandran | Director | A | +7,970 | — |
| 2025-06-13 | David D. Meek | Director | A | +7,970 | — |
| 2025-06-13 | Jack Kaye | Director | A | +7,970 | — |
| 2025-06-13 | Leonard E Post | Director | A | +7,970 | — |
| 2025-06-13 | Robert Gut | Director | A | +7,970 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Matthew C Kapusta | CEO, Managing Director | 519,227 | $12.94M |
| Christian Klemt | Chief Financial Officer | 226,581 | $5.65M |
| Walid Abi-Saab | Chief Medical Officer | 178,235 | $4.44M |
| Jeannette Potts | Chief Legal Officer | 133,246 | $3.32M |
| Kylie O'Keefe | Chief Customer & Strat Officer | 108,864 | $2.71M |
| Madhavan Balachandran | Director | 43,254 | $1.08M |
| Jeremy P. Springhorn | Director | 43,251 | $1.08M |
| Jack Kaye | Director | 43,056 | $1.07M |
| David D. Meek | Director | 41,740 | $1.04M |
| Rachelle Suzanne Jacques | Director | 35,896 | $894.89K |
| Leonard E Post | Director | 35,494 | $884.87K |
| Robert Gut | Director | 32,342 | $806.29K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the QURE quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.